作者发现了一个新的肿瘤标志物MA153，其化学结构为Mu-GlcNAc（粘蛋白1-N-乙酰氨基葡萄糖），它可与单克隆抗体Ma695和相关Aptamer（适配体MA153-A）形成Ma695-Mu-GlcNAc-MA153-A式的夹心反应。临床血清学检测表明，Mu-GlcNAc存在于癌症患者血中，以1U/mL为正常界值，Mu-GlcNAc的肿瘤特异度达95%，癌症检出的灵敏度对乳腺癌、胰腺癌、肝癌、肺癌、食管癌、口腔癌、结肠癌、胆管癌、卵巢癌、宫颈癌、子宫癌，分别为80%、74%、68%、70%、75%、50%、60%、55%、70%、64%、60%。本研究资料显示，Mu-GlcNAc是一个新的良好广谱肿瘤标志物。

We discovered a new tumor marker MA153 which has been identified as Mu-GlcNAc (Mucin1-N-acetyl-Glucosamine). It can react with monoclonal antibody and a related Aptamer to form the Ma695-Mu-GlcNAc-MA153-A sandwich assay. Taking 1 u/mL as cutoff value, the clinical serum detection results indicated that the tumor specificity of Mu-GlcNAc was 95%, the tumor detection sensitivities were 80%, 74%, 68%, 70%, 75%, 50%, 60%, 55%, 70%，64%, and 60% for breast cancer, pancreatic cancer, liver cancer, lung cancer, esophagus cancer, mouth cancer, colon cancer, bile duct cancer, ovarian cancer, cervix cancer and uterus cancer, respectively. It is concluded that Mu-GlcNAc is a new multi-tumor tumor marker.